Medical journal, Armed Forces India · 2025
Phase III, randomized, single blind, comparative safety, and efficacy trial of intravenous iron isomaltoside (i3R) and ferric carboxy maltose in subjects with iron deficiency anaemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yanamandra Uday, Harikrishnan P, Erappa Himanth, Singh Santosh Kumar, Verghese Renjith, Agarwal Deeptika, Yadav A K, Gupta Anurodh, Muthukrishnan J
Аннотация
BACKGROUND: Iron Deficiency Anemia (IDA) is a significant global health issue managed routinely with oral iron. However, its effectiveness is limited by dietary absorption factors and gastrointestinal (GI) side effects requiring parenteral iron therapies. This study compares the safety and efficacy of parenteral iron preparations, Iron Isomaltoside (i3R), and Ferric Carboxymaltose (FCM) in IDA.
METHODS: This is a single-center investigator-initiated randomized, phase III single-blind trial in Western India from January 2023 to July 2024. 280 participants with IDA and GI intolerance were assigned to receive 1000 mg IV infusion of either i3R or FCM. Patients were followed up at 4, 12, and 24 weeks for changes in hemoglobin (Hb) and Ferritin from baseline, along with safety evaluations.
RESULTS: The mean change in Hb and mean Hb across the time intervals were comparable in both arms; however, the i3R arm had higher mean ferritin/ mean change in ferritin levels at 12 and 24 weeks (p < 0.05) with no age and gender difference in the subgroup analysis. Safety profiles in both arms were comparable.
CONCLUSION: The study demonstrates the comparable efficacy of i3R and FCM in improving Hb and serum ferritin levels in IDA patients. Both treatments demonstrated safety and tolerability in a well-designed RCT.
METHODS: This is a single-center investigator-initiated randomized, phase III single-blind trial in Western India from January 2023 to July 2024. 280 participants with IDA and GI intolerance were assigned to receive 1000 mg IV infusion of either i3R or FCM. Patients were followed up at 4, 12, and 24 weeks for changes in hemoglobin (Hb) and Ferritin from baseline, along with safety evaluations.
RESULTS: The mean change in Hb and mean Hb across the time intervals were comparable in both arms; however, the i3R arm had higher mean ferritin/ mean change in ferritin levels at 12 and 24 weeks (p < 0.05) with no age and gender difference in the subgroup analysis. Safety profiles in both arms were comparable.
CONCLUSION: The study demonstrates the comparable efficacy of i3R and FCM in improving Hb and serum ferritin levels in IDA patients. Both treatments demonstrated safety and tolerability in a well-designed RCT.